A 23-year-old woman underwent HLA-matched unrelated BMT for CML. She developed cerebral blindness on day 81. Brain magnetic resonance imaging revealed hyperintensity on a T2-weighted image in the white and gray matter of the right frontal and both occipital lobes. Single-photon emission computed tomography (SPECT) was consistent with a decrease in radionuclide uptake in these areas, suggesting a vasoconstrictive mechanism. A diagnosis of CsA-induced encephalopathy was made and CsA was discontinued. Her vision recovered completely after 24 h and abnormal imaging resolved within 2 weeks. This case demonstrates late onset CsA-induced cerebral blindness with the previously unreported abnormalities on SPECT. Bone Marrow Transplantation (2000) 26, 105-108.
Cyclosporin A (CsA) is a potent immunosuppressive agent used in organ and bone marrow transplantation (BMT) for prophylaxis of rejection and graft-versus-host disease (GVHD). Some side-effects and toxicities, including nephrotoxicity, hepatoxicity, hypertension and neurotoxicity, may be serious. Neurological complications have been noted with increasing frequency and cause morbidity and mortality in up to 37% of patients undergoing allogenic BMT. 1 CsA is considered as a significant contributor to these complications. Clinical features of CsA neurotoxicity include tremors, headaches, seizures, altered mental function, confusion, and visual hallucinations. Cerebral blindness is a rare manifestation of CsA neurotoxicity and often precedes the development of seizures, and accompanies radiographically characteristic white matter abnormalities often involving the occipital lobes. We present a case of late onset reversible cerebral blindness in a recipient of unrelated BMT with the previously unreported abnormalities on single-photon emission computed tomography (SPECT).
Case report
A 23-year-old woman was diagnosed as being in the chronic phase of chronic myelogenous leukemia in April 1996. She was treated with alfa-interferon and hydroxyurea. However, she showed no cytogenetic response. On 15 May 1998, she received an unrelated BMT following a preparative regimen of ranimustine (150 mg/body), cyclophosphamide (120 mg/kg), splenic irradiation (800 cGy over 4 days) and fractionated total body irradiation (1200 cGy over 4 days). GVHD prophylaxis consisted of a short course of methotrexate and CsA, 3 mg/kg twice daily p.o., beginning 1 day before BMT. She received G-CSF from day 5 to day 20 after BMT. Pre-transplant neurogenic evaluation was normal. The patient made excellent hematopoietic recovery. Her neutrophil count on day 16 was 0.7 × 10 9 /l. On day 17, she developed grade I acute GVHD and was treated with prednisolone 100 mg/body. Prednisolone was gradually tapered and was stopped on day 71 after transplantation. She received ganciclovir intermittently from day 42 to day 75 as pre-emptive therapy for cytomegalovirus infection. Until day 78, her CsA trough level was within the therapeutic range (170-250 ng/ml). On day 80, she complained of a severe headache and 20 h later, developed blurring of vision which rapidly progressed to complete blindness over a period of 3 h. On physical examination, she was alert, had a low-grade fever, blood pressure of 124/80, pulse 80 per min and an intention tremor. Over the next 10 h, she went on to transiently develop somnolence. Fundoscopic examination was normal. Routine blood chemistries including LDH level were normal. There was no increase in fragmented red blood cells in the peripheral blood. Her CsA trough level was 425 ng/ml, although there was no deterioration in renal function and she did not receive any drugs likely to increase her CsA level. Serum levels of magnesium and cholesterol were 0.699 mmol/l and 6.21 mmol/l, respectively. Coagulation tests revealed slight prolongation of prothrombin time and activated partial thromboplastin time, but the fibrin degradation product Bone Marrow Transplantation the posterior head region. A diagnosis of CsA toxicity with secondary encephalopathy and cerebral blindness was made. The CsA was discontinued and prednisolone was started as GVHD prophylaxis. Her visual abnormality completely resolved within 24 h and disorientation gradually improved over several days. Repeated CT on day 87 showed decreasing abnormal signs and the MRI obtained on day 95 revealed improvement in all the abnormal regions. An attempt to reintroduce CsA in an oral dose of 75 mg/day was made on day 85, achieving CsA trough level ranging from 35 to 95 ng/ml. Within 10 days of this, she developed blurring of vision again. CsA was again discontinued and she was treated with prednisolone only. Although the patient had residual abnormalities on followup EEG for 2 months, EEG on day 147 revealed normal The dynamic images were obtained with rotating gamma camera and quantification was performed by the Patlak plot method. The cerebral blood flow in the hemisphere of the normal control group showed 50-60 ml/100 mg/min. The cerebral blood flow in this case was decreased in the frontal lobes and parieto-occipital areas.
finding. She developed interstitial pneumonia on day 124 and was treated with high-dose methylprednisolone. Currently, she is alive and well over 17 months after BMT without recurrence of any neurological symptoms and on no medication.
Discussion
A recent report showed that CsA neurotoxicity was seen more frequently and earlier after BMT in HLA-mismatched or unrelated BMT recipients. 2 Cerebral blindness typically occurs within the first month of CsA therapy. 3 In addition, it has been reported that such recipients have a very poor prognosis with a short survival after developing CsA neurotoxicity. 4 Furthermore, it was suggested that cerebral cell death and permanent cerebral injury might occur. 2 In contrast to these reports, this patient developed the adverse event later in the course of BMT and she is alive and well over 17 months after developing cerebral blindness. However, in this case, the gray matter of the occipital lobes was involved in addition to typical abnormal findings in the white matter on MRI. Zimmer et al 2 proposed that cortical signal abnormality reflects severe cellular injury. Thus, the finding in this case may indicate more extensive cellular injury in unrelated BMT recipients.
The pathogenesis of CsA-induced cerebral blindness is not clear at present. In this case, no contributing factors were identified except for the rapid and transient rise in plasma CsA level. Moreover, there was no evidence of transplantation-associated thrombotic microangiopathy (TMA), which is suggested to have a strong association with CsA-induced neurotoxicity. 3 Acute GVHD, which is considered to accelerate endothelial cell damage and be the most significant risk factor for microangiopathy, 5 may have contributed to the development of cerebral blindness in this case.
Recently, the similarity in clinical findings and neuroimaging between CsA neurotoxicity, hypertensive encephalopathy, and eclampsia has been noted, and a new clinical entity of reversible posterior leukoencephalopathy syndrome is proposed by Hinchey et al. 6 Hypertensive
Bone Marrow Transplantation encephalopathy is hypothesized to result from a loss of cerebral autoregulation with sudden elevation with systemic blood pressure, focal vasoconstriction or vasodilatation, and breakdown of the blood-brain barrier with focal transduction of fluid. 7 However, since CsA neurotoxicity occurs at a lower blood pressure, 8 it seems likely that there is a difference in pathogenesis between both. In this case, SPECT was used to investigate regional brain perfusion. SPECT characteristics have not been described in previous cases with CsA neurotoxicity. Schwartz et al 7 showed focal enhancement on an MRI with gadopentetate dimeglumine, and increased uptake of radionuclides on a SPECT with 99m Tc-hexamethylpropyleneamine oxime during the hypertensive crisis phase of hypertensive encephalopathy. Based on these findings, they proposed that vasogenic edema leads to hypertensive encephalopathy. However, we found uptake of radionuclides to be decreased in the frontal lobe and parieto-occipital region in this case ( Figure 2 , Table 1 ). This fact suggests a vasoconstrictive mechanism in the pathogenesis of CsA-induced cerebral blindness. However, cerebral hyperperfusion in the early phase of cerebral blindness may have been missed and we only detected vasospasm and transient hypoperfusion after cerebral regional edema, because the patient was imaged late (3 days) after the onset of neurological symptoms. Furthermore, we are unable to explain why the cerebral blood flow of frontal lobe on both sides was decreased, but on MRI only a unilateral lesion was found. Other contributing factors may be necessary for regional cerebral edema to develop. Detailed examination of SPECT and MRI with numerous similar cases will be necessary for further evaluation of the pathogenesis of CsA neurotoxicity.
